Fusing Science, Technology & Industry Leadership
February 22-23, 2010
Raleigh, NC
CEOs From Two of the Largest 2009 Deals Confirmed
CED's Biotech 2010 features remarks from the former CEO of CV Therapeutics, Inc. (acquired by Gilead Sciences) and the CEO of Talecris Biotherapeutics.
Dr.
Louis Lange, PhD, currently a general partner with Asset Management,
founded CV Therapeutics, Inc. and led initiatives that resulted in an
acquisition by Gilead Sciences for $1.4 billion.
Talecris Biotherapeutics CEO, Larry
Stern joins a featured panel on financing. Together with the following
panelists, he explores the different sources of available capital.
- Stephen Sands, Vice Chairman, US Investment
Banking and Global Co-Head, Lazard's Healthcare Group (Moderator)
- John Clerici, Partner
and Chair, Life Sciences and Public Health Preparedness Practice, McKenna
Long & Aldridge LLP
- Ed Mathers, Partner,
NEA
- Lauren Silverman, Managing Director, Novartis
Option Fund
- Lawrence (“Larry”) D. Stern, Chairman and CEO, Talecris Biotherapeutics
Take
advantage of early registration rates and save $100 before January 20. Click
here to register.
